skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: I have no Healthcare companies in my portfolio. What names are you presently recommending; Canadian and/or US $. Thanks.
Read Answer Asked by Gerry on January 05, 2023
Q: The top 10 holdings (50% +) have a dividend yield of 0 to 4 % yield. The ETF shows a yield of 8.46%. Could you explain the discrepancy ? I like the sector. Beside HHL could recommend a other ETF.
Read Answer Asked by ray on January 04, 2023
Q: This US REIT has been beaten and sits near its 2022 low with a healthy divvy. It holds quality medical offices located near hospitals which should provide it with some pricing power with doctors wanting to locate close to where they perform surgeries. Is the dividend safe? How would you categorize their debt? Is this one you'd recommend or avoid? Any other concerns? Lastly how does this compare with MPW? Appreciate your views.
Read Answer Asked by Ken on January 04, 2023
Q: hi folks:

below is your reply/update from july 12,2022 on these 4 pot stocks

seems like the only catalyst will be the pending legislative change in the usa

i am curious for your update on these names, with a comment on potential survivability (or, i guess, lack of same)


thanks again

merry christmas to you and your families


unless that offends you, then happy holidays...............


july2022
GRWG is the smallest of the names, with a market cap of $256.3M, whereas GTII has a market cap of $2.8B, TRUL $3.0B, and CURA $4.6B. Revenue growth is strong among all four companies. GRWG has had the most volatility in price and its balance sheet is quite strong, but it does issue shares to fund its operations. GTII has good profit margins and is at a reasonable valuation (2.0X sales, 30.1X P/E, and 1.3X book value). TRUL has shown volatility in its profitability and its valuation is OK (1.7X sales, 37.3X P/E, and 1.0X book). CURA is not profitable and has a high valuation.

We think that GTII has demonstrated its resiliency and is the strongest of the four names. Although GRWG is the smallest, we like its profitability and strong balance sheet. We would then rank TRUL and CURA following GTII and GRWG. Although, the momentum in shares for all four names is not the greatest and we would prefer to wait until investor appetite for growth stocks has returned before becoming interested in these names.

Read Answer Asked by Robert on January 04, 2023
Q: I checked out the 5i Profile page for Theratechnologies to see if there was any news regarding the large drop on December 1st but didn't see anything. I checked out Theratechnologies Investor Relations website and found the press release regarding the enrollment pause on the Phase 1 clinicial trial of TH1902. Why doesn't this press release show up in the News & Media section on TH's Profile in 5i?
Read Answer Asked by Ray on December 21, 2022
Q: Trying to wrap my mind around Well. It’s current financial status and future potential. Are you able to outline balance sheet, cash flow, profitability, growth and upside potential etc. Isn’t this a good sector to be in during these times? It looks significantly discounted from where it was. What are the risks. Thx.
Read Answer Asked by Chris on December 20, 2022
Q: Hi Peter,
I don't have any positions in the Health Care sector. Please provide a few suggestions, either stocks and/or ETFs, for both Canada and USA. I would like the Buy and Hold for say 5 years or more strategy.
Many thanks,
Roger
Read Answer Asked by Roger on December 19, 2022
Q: Season's greetings - what are your thoughts on MRNA. The skin cancer test results lofted the shares yesterday. It still seems inexpensive, given a sub six PE. I have a small holding and am thinking of investing more. It's well within my portfolio recommendations. Don't understand why it not getting more love with all the viruses running around the world. Thanks
Read Answer Asked by alex on December 16, 2022
Q: Further to your response to Tom on Dec. 5th, could you recommend several ETFs that would be quality choices to represent emerging markets, healthcare and tech that would result in less overall volatility than purchasing individual stocks? Thanks.
Read Answer Asked by Tara on December 13, 2022